Page last updated: 2024-12-05

pimethixene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pimethixene: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4822
CHEMBL ID152408
CHEBI ID94787
SCHEMBL ID301596
MeSH IDM0045352

Synonyms (79)

Synonym
AC-13161
BRD-K88090157-050-04-1
DIVK1C_000432
KBIO1_000432
SPECTRUM_001324
OPREA1_122930
NCGC00016698-01
D07406
314-03-4
pimethixene (inn)
calmixene (tn)
BSPBIO_000228
BSPBIO_002901
SPECTRUM5_001353
IDI1_000432
pimethixene [inn]
calmixene
9-(1-methyl-4-piperidylidene)thioxanthene
pimethixene
mepithiathene
bp 400
pimethixenum [inn-latin]
1-methyl-4-(thioxanthen-9-ylidene)piperidine
pimetixeno [inn-spanish]
piperidine, 1-methyl-4-thioxanthen-9-ylidene-
brn 4143937
einecs 206-240-4
calmixen
piperidine, 1-methyl-4-(9h-thioxanthen-9-ylidene)-
AB00053710
bp-400
KBIOSS_001804
KBIO2_004372
KBIO3_002401
KBIO2_001804
KBIO2_006940
KBIOGR_000748
PRESTWICK1_000294
NINDS_000432
SPECTRUM3_001441
SPBIO_002447
SPECTRUM4_000424
PRESTWICK0_000294
PRESTWICK2_000294
BPBIO1_000252
PRESTWICK3_000294
NCGC00016698-02
NCGC00016698-03
nsc-757828
pimetixene
CHEMBL152408 ,
1-methyl-4-(9h-thioxanthen-9-ylidene)piperidine
1-methyl-4-thioxanthen-9-ylidene-piperidine
bdbm50097224
1-methyl-4-thioxanthen-9-ylidenepiperidine
pimetixeno
nsc 757828
unii-t46j20j26f
pimethixenum
t46j20j26f ,
AKOS015850901
SCHEMBL301596
pimethixene [mart.]
pimethixene [who-dd]
CS-4692
DTXSID0048476
pimethixen
NZLVRVYNQYGMAB-UHFFFAOYSA-N
HY-B1101
AB00053710_06
1-methyl-4-(9-thioxanthenylidene)piperidine
CHEBI:94787
SBI-0051926.P002
E73927
DB13292
Q6676377
BRD-K88090157-050-06-6
BS-49377
EN300-18563908
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thioxanthenesThioxanthene and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Pimethixene H1-Antihistamine Action87

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID504865
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency3.98110.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency15.84890.00255.840031.6228AID899
lethal factor (plasmid)Bacillus anthracis str. A2012Potency10.00000.020010.786931.6228AID912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transcriptional activator protein LuxRAliivibrio fischeriIC50 (µMol)56.00001.36003.25337.0000AID493958
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.00250.00010.601710.0000AID5514
Histone-lysine N-methyltransferase SETD7Homo sapiens (human)IC50 (µMol)4.30000.00202.52666.0800AID1311948
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
DNA damage responseHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
heterochromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin remodelingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
peptidyl-lysine monomethylationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
response to ethanolHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
heterochromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
p53 bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone H3 methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone H3K4 monomethyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleoplasmHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromosomeHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
nucleolusHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromosomeHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1311948Inhibition of recombinant SET7/9 (unknown origin) using biotinylated histone H3-derived peptide/SAM as substrate after 60 mins by AlphaLISA assay2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Steric structure-activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7/9.
AID493961Induction of of LuxR-dependent quorum sensing in Vibrio fischeri assessed as induction of bioluminescence intensity up to 200 uM2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
LuxR-dependent quorum sensing: computer aided discovery of new inhibitors structurally unrelated to N-acylhomoserine lactones.
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1311949Displacement of [3H]ketanserin from Sprague-Dawley rat cerebral cortex 5-HT2A receptor after 30 mins by liquid scintillation counting analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Steric structure-activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7/9.
AID5514Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin receptor.
AID493958Inhibition of LuxR-dependent quorum sensing in Vibrio fischeri assessed as reduction of 3-oxo-C6-HSL-induced bioluminescence intensity2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
LuxR-dependent quorum sensing: computer aided discovery of new inhibitors structurally unrelated to N-acylhomoserine lactones.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (46.15)18.7374
1990's0 (0.00)18.2507
2000's2 (15.38)29.6817
2010's4 (30.77)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.27 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]